Analysts’ Weekly Ratings Changes for Amphastar Pharmaceuticals (AMPH)

Amphastar Pharmaceuticals (NASDAQ: AMPH) has recently received a number of price target changes and ratings updates:

  • 3/13/2019 – Amphastar Pharmaceuticals was downgraded by analysts at Piper Jaffray Companies from an “overweight” rating to a “neutral” rating. They now have a $23.00 price target on the stock, down previously from $24.00.
  • 3/13/2019 – Amphastar Pharmaceuticals was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating. They now have a $22.20 price target on the stock.
  • 3/5/2019 – Amphastar Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 3/3/2019 – Amphastar Pharmaceuticals was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 2/27/2019 – Amphastar Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 2/25/2019 – Amphastar Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 2/20/2019 – Amphastar Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 2/14/2019 – Amphastar Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 2/5/2019 – Amphastar Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “
  • 1/24/2019 – Amphastar Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. “

AMPH traded down $0.27 during mid-day trading on Friday, hitting $20.23. The stock had a trading volume of 663,688 shares, compared to its average volume of 202,857. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.34 and a current ratio of 2.02. The firm has a market cap of $1.11 billion, a PE ratio of 96.33, a price-to-earnings-growth ratio of 1.81 and a beta of 1.40. Amphastar Pharmaceuticals Inc has a 1-year low of $14.40 and a 1-year high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.02. The company had revenue of $89.69 million for the quarter, compared to analyst estimates of $75.46 million. Amphastar Pharmaceuticals had a negative net margin of 1.96% and a positive return on equity of 3.25%. Equities analysts forecast that Amphastar Pharmaceuticals Inc will post 0.54 EPS for the current fiscal year.

In related news, CFO William J. Peters sold 1,500 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $25.36, for a total transaction of $38,040.00. Following the sale, the chief financial officer now directly owns 77,050 shares in the company, valued at $1,953,988. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Rong Zhou sold 3,200 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $25.00, for a total transaction of $80,000.00. Following the sale, the executive vice president now owns 55,230 shares in the company, valued at $1,380,750. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 87,222 shares of company stock worth $2,037,797. 31.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in AMPH. Renaissance Technologies LLC grew its position in shares of Amphastar Pharmaceuticals by 104.3% in the 3rd quarter. Renaissance Technologies LLC now owns 186,100 shares of the company’s stock valued at $3,581,000 after acquiring an additional 95,000 shares during the period. Rothschild & Co. Asset Management US Inc. grew its position in shares of Amphastar Pharmaceuticals by 4.3% in the 4th quarter. Rothschild & Co. Asset Management US Inc. now owns 335,930 shares of the company’s stock valued at $6,685,000 after acquiring an additional 13,757 shares during the period. MetLife Investment Advisors LLC grew its position in shares of Amphastar Pharmaceuticals by 54.3% in the 3rd quarter. MetLife Investment Advisors LLC now owns 28,086 shares of the company’s stock valued at $540,000 after acquiring an additional 9,881 shares during the period. Man Group plc grew its position in shares of Amphastar Pharmaceuticals by 55.1% in the 3rd quarter. Man Group plc now owns 18,451 shares of the company’s stock valued at $355,000 after acquiring an additional 6,556 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Amphastar Pharmaceuticals by 3.6% in the 3rd quarter. Legal & General Group Plc now owns 74,224 shares of the company’s stock valued at $1,425,000 after acquiring an additional 2,568 shares during the period. 48.22% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Featured Article: Current Ratio

Receive News & Ratings for Amphastar Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.